Ozarelix

DRUG3 trials

Sponsors

Spectrum Pharmaceuticals, Inc

Conditions

Benign Prostatic Hyperplasia (BPH)Benign Prostatic HypertrophyLower Urinary Tract Symptoms (LUTS)Prostate Cancer

Phase 2

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

CompletedNCT00427219

Spectrum Pharmaceuticals, IncBenign Prostatic Hypertrophy

Start: 2007-01-23End: 2008-02-27Updated: 2021-10-15

Trial of the Safety and Efficacy of Ozarelix in Participants With Benign Prostatic Hyperplasia (BPH)

TerminatedNCT00743184

Spectrum Pharmaceuticals, IncBenign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS)

Start: 2008-12-04End: 2010-01-20Updated: 2021-11-22

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

CompletedNCT01252693

Spectrum Pharmaceuticals, IncProstate Cancer

Start: 2010-11-30End: 2015-05-31Updated: 2021-10-05